The field of in vivo screening is continually evolving with advancements in technology and methodology:
Improved imaging techniques: Advanced imaging technologies, such as MRI and PET scans, allow for non-invasive monitoring of tumor growth and treatment response. Genomic and proteomic analyses: High-throughput sequencing and proteomic technologies provide deeper insights into the molecular mechanisms of drug action and resistance. Humanized mouse models: Mice engineered to carry human genes, tissues, or immune cells offer more accurate models of human cancer biology. 3D bioprinting: The use of 3D bioprinting to create more complex and physiologically relevant tumor models is an emerging area of research.
